Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently updated its clinical study ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

The stock's fall snapped a seven-day winning streak.

Incyte commences Dutch Auction tender offer to repurchase up to $1.67 billion of outstanding common shares May 13, 2024 07:00 AM Eastern Daylight Time ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

Incyte will host an in-person analyst and investor event today from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) to discuss key data presentations at ESMO including data from the POD1UM-303 ...

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463. are breastfeeding or plan to breastfeed.